Drug search by name

Didanosine Delayed-Release Enteric-Coated Capsules and Hyperuricemia

Result of checking the interaction of drug Didanosine Delayed-Release Enteric-Coated Capsules and disease Hyperuricemia for safety when used together.

Check result:

Didanosine Delayed-Release Enteric-Coated Capsules <> Hyperuricemia

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Didanosine (ddI) may infrequently cause hyperuricemia. Patients with preexisting hyperuricemia or gout should be monitored for exacerbation of condition during ddI therapy.

References:

"Product Information. Videx (didanosine)." Bristol-Myers Squibb, Princeton, NJ.
Mehlhaff DL, Stein DS "Gout secondary to ritonavir and didanosine." AIDS 10 (1996): 1744
Schindzielorz A, Pike I, Daniels M, Pacelli L, Smaldone L "Rates and risk factors for adverse events associated with didanosine in the expanded access program." Clin Infect Dis 19 (1994): 1076-83
Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993): S63-8

Didanosine Delayed-Release Enteric-Coated Capsules

Generic Name: didanosine

Brand Name: Videx, Videx EC

Synonyms: Didanosine

What is Didanosine Delayed-Release Enteric-Coated Capsules?